Cobimetinib (Cotellic®)

Assessment Status NCPE Assessment process complete
Drug Cobimetinib
Brand Cotellic®
Indication For use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
Assessment Process
Rapid review commissioned 19/04/2016
Rapid review completed 26/04/2016
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 18/07/2016
NCPE assessment completed 05/01/2017
NCPE assessment outcome Reimbursement Not Recommended at the Submitted Price.

The NCPE does not consider cobimetinib (Cotellic®) with vemurafenib (Zelboraf®) cost-effective for the treatment of advanced (unresectable or metastatic) melanoma with the BRAF V600 mutation and therefore it is not recommended for reimbursement at the submitted price.

The HSE has approved reimbursement following confidential price negotiations; April 2018.

Technical Summary